Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance
Globe Newswire•13/11/2026•08:05 ET
0
Key Highlights
- ➤$24.1 million cash and restricted cash at September 30, 2026
- ➤Fourth-quarter EPS guidance $0.01-$0.04, driven by debt extinguishment gain
- ➤Full-year 2026 loss guidance $0.73-$0.76 per share
- ➤Novartis settlement cuts $4.9 million liability to $1.0 million payment
- ➤R&D expenses rose to $4.2 million on $3.2 million stenoparib manufacturing charge
Expert Statements
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“Completing API manufacturing gives us a head start on drug supply for a potential Phase 3 trial of stenoparib in advanced ovarian cancer while enrollment continues in our Phase 2 studies.”
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“We resolved a significant legacy liability and the expected gain from that settlement is the primary driver of our fourth-quarter earnings guidance.”
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“Our first contract under the CLIA laboratory services strategy is an early step toward generating revenue from capabilities we built for our own development programs.”
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“We're also strengthening the intellectual property behind those programs, with a newly granted Japanese patent that protects our stenoparib DRP® companion diagnostic into 2039.”
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“Our priority is to build the clinical evidence that will guide the next stage of stenoparib development.”
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“As we advance that work, we're focused on delivering for our first CLIA services customer and building a laboratory business that can generate revenue alongside our clinical programs.”
Ended third quarter with $24.1 million in cash and restricted cash
Expects positive fourth quarter earnings between $0.01 and $0.04 per share
Get started
Create a free account to read the full story.